BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32978525)

  • 21. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
    Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
    J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of
    Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
    J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy.
    Murphy AM; Berkman DS; Desai M; Benson MC; McKiernan JM; Badani KK
    BJU Int; 2010 Jan; 105(2):176-9. PubMed ID: 19549117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    Meijer D; Ettema RH; van Leeuwen PJ; van der Kwast TH; van der Poel HG; Donswijk ML; Oprea-Lager DE; Bekers EM; Vis AN
    BJU Int; 2023 Mar; 131(3):330-338. PubMed ID: 36069585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial.
    Harke NN; Godes M; Wagner C; Addali M; Fangmeyer B; Urbanova K; Hadaschik B; Witt JH
    World J Urol; 2018 Nov; 36(11):1817-1823. PubMed ID: 29767326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [
    Grubmüller B; Jahrreiss V; Huebner N; Mitterhauser M; Stangl-Kremser J; Grubmüller KH; Baltzer P; Hacker M; Goldner G; Shariat SF; Rasul S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):439-447. PubMed ID: 32994534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
    Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
    World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
    Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
    BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases.
    Tsaur I; Hennenlotter J; Oppermann E; Munz M; Kuehs U; Stenzl A; Schilling D
    Cancer Biomark; 2015; 15(3):311-6. PubMed ID: 25769446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
    Shiota M; Takamatsu D; Matsui Y; Yokomizo A; Morizane S; Saito R; Miyake M; Tsutsumi M; Yamamoto Y; Tashiro K; Tomida R; Narita S; Edamura K; Yamaguchi T; Hashimoto K; Kato M; Kasahara T; Yoshino T; Akamatsu S; Kaneko T; Matsukawa A; Matsumoto R; Joraku A; Saito T; Kato T; Kato M; Enokida H; Sakamoto S; Terada N; Kanno H; Nishiyama N; Kimura T; Kitamura H; Eto M;
    Ann Surg Oncol; 2024 Jun; 31(6):3872-3879. PubMed ID: 38353798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
    Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
    Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases.
    Lunger L; Steinhelfer L; Korn P; Eiber M; Maurer T; Büchler J; Horn T; Gschwend JE; Heck MM
    Eur Urol Oncol; 2023 Feb; 6(1):95-98. PubMed ID: 36604297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.